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MR-proADM as a Prognostic Marker in Patients With
ST-Segment–Elevation Myocardial Infarction—DANAMI-3
(a Danish Study of Optimal Acute Treatment of Patients With STEMI)
Substudy
Alexander C. Falkentoft, MB; Rasmus Rørth, MD; Kasper Iversen, MD, DMSc; Dan E. Høfsten, MD, PhD; Henning Kelbæk, MD, DMSc;
Lene Holmvang, MD, DMSc; Martin Frydland, MD; Mikkel M. Schoos, MD, PhD; Steffen Helqvist, MD, DMSc; Anna Axelsson, MD, PhD;
Peter Clemmensen, MD, DMSc; Erik Jørgensen, MD; Kari Saunam€aki, MD, DMSc; Hans-Henrik Tilsted, MD, PhD; Frants Pedersen, MD,
PhD; Christian Torp-Pedersen, MD, DMSc; Klaus F. Kofoed, MD, PhD, DMSc; Jens P. Goetze, MD, DMSc; Thomas Engstrøm, MD, PhD,
DMSc; Lars Køber, MD, DMSc
Background-—Midregional proadrenomedullin (MR-proADM) has demonstrated prognostic potential after myocardial infarction
(MI). Yet, the prognostic value of MR-proADM at admission has not been examined in patients with ST-segment–elevation MI
(STEMI).
Methods and Results-—The aim of this substudy, DANAMI-3 (The Danish Study of Optimal Acute Treatment of Patients with ST-
segment–elevation myocardial infarction), was to examine the associations of admission concentrations of MR-proADM with short-
and long-term mortality and hospital admission for heart failure in patients with ST-segment–elevation myocardial infarction.
Outcomes were assessed using Cox proportional hazard models and area under the curve using receiver operating characteristics.
In total, 1122 patients were included. The median concentration of MR-proADM was 0.64 nmol/L (25th–75th percentiles, 0.53–
0.79). Within 30 days 23 patients (2.0%) died and during a 3-year follow-up 80 (7.1%) died and 38 (3.4%) were admitted for heart
failure. A doubling of MR-proADM was, in adjusted models, associated with an increased risk of 30-day mortality (hazard ratio,
2.67; 95% conﬁdence interval, 1.01–7.11; P=0.049), long-term mortality (hazard ratio, 3.23; 95% conﬁdence interval, 1.97–5.29;
P<0.0001), and heart failure (hazard ratio, 2.71; 95% conﬁdence interval, 1.32–5.58; P=0.007). For 30-day and 3-year mortality,
the area under the curve for MR-proADM was 0.77 and 0.78, respectively. For 3-year mortality, area under the curve (0.84) of the
adjusted model marginally changed (0.85; P=0.02) after addition of MR-proADM.
Conclusions-—Elevation of admission MR-proADM was associated with long-term mortality and heart failure, whereas the
association with short-term mortality was borderline signiﬁcant. MR-proADM may be a marker of prognosis after ST-segment–
elevation myocardial infarction but does not seem to add substantial prognostic information to established clinical models.
Clinical Trial Registration-—URL: http:/www.ClinicalTrials.gov/. Unique identiﬁers: NCT01435408 and NCT01960933. ( J Am
Heart Assoc. 2018;7:e008123. DOI: 10.1161/JAHA.117.008123.)
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M yocardial infarction remains a major cause of mortalityand morbidity worldwide.1 The current preventive
strategies and recommendations of early reperfusion with
primary percutaneous coronary intervention (PCI) have
improved the outcomes in patients with ST-segment–
elevation myocardial infarction (STEMI).2,3 However, mortality
remains substantial and cardiovascular causes, including
heart failure, remain the leading causes of mortality during
the ﬁrst month after STEMI.4,5 Therefore, early assessment of
risk is important for effective and alert management of
patients, after reperfusion is achieved.
Adrenomedullin (ADM) is a 52-amino-acid peptide derived
from a larger precursor termed pre-proadrenomedullin (185
amino-acid residues). It was originally isolated from human
pheochromocytoma tissue and has subsequently been
detected in several human tissues including the adrenal
medulla, heart, lung, kidney, gastrointestinal organs, brain,
vascular endothelium, and vascular smooth muscle cells.6–8
ADM causes potent vasodilation and hypotension, increases
cardiac output, and induces diuresis and natriuresis;6,9
elevated levels of ADM in myocardial infarction and in heart
failure10–13 have been shown to be associated with adverse
outcomes.14,15 Despite this, it has been technically difﬁcult to
introduce ADM as a biomarker in plasma because of
instability in vivo.16,17 This has been solved by developing
an assay for measurement of the stable peptide fragment
midregional proadrenomedullin (MR-proADM). It is generated
from post-translational processing of pre-proadrenomedullin
and is secreted in equimolar amounts to ADM.18
The prognostic value of MR-proADM concentrations at admis-
sion has not been examined in a large STEMI cohort prior to PCI.
We examined the associations of MR-proADM concentrations
at admission with short- and long-term mortality and hospital
admission for heart failure in patients with STEMI undergoing PCI.
Methods
The data, analytic methods, and study materials will be made
available to other researchers for purposes of reproducing the
results or replicating the procedure. All data are stored
electronically at the Clinical Trial Unit at Rigshospitalet and
can be available for other researchers by contacting members
(Thomas Engstrøm or Lars Køber) of the DANAMI-3 (The
Danish Study of Optimal Acute Treatment of Patients with ST-
segment–elevation myocardial infarction) steering committee
afﬁliated to Rigshospitalet.
Study Design and Patients
This study was a post hoc substudy of the DANAMI-3 trial
program. The rationale and design of the DANAMI-3
trial program has previously been reported.19 In short, the
program comprised three randomized controlled multicenter
trials investigating the effect of: (1) ischemic post-condition-
ing induced by repetitive interruptions of blood ﬂow
immediately after reopening versus conventional primary
PCI, DANAMI-3-iPOST;20 (2) deferred stent implantation in
the infarct-related lesion vs conventional primary PCI with
immediate stent implantation, DANAMI-3-DEFER;21 and
(3) fractional ﬂow reserve-guided complete revascularization
versus treatment of the culprit lesion only in patients with
multivessel disease, DANAMI-3-PRIMULTI.22 The program
included patients (aged >18 years) admitted to the hospital
with chest pain of <12 hours duration and ST-segment–
elevation greater than 0.1 mV in at least 2 contiguous leads
or documented newly developed left bundle-branch block.
Major exclusion criteria were the inability to provide consent
because of unconsciousness or cardiogenic shock, stent
thrombosis, or need of acute coronary artery bypass surgery.
All patients included in this single center substudy were
referred to Rigshospitalet, Copenhagen, (1 of the 4 primary
PCI centers in DANAMI-3) and had blood samples obtained at
admission for MR-proADM measurement.
Clinical Perspective
What Is New?
• This study demonstrates that elevation of midregional
proadrenomedullin from blood samples taken immediately
at presentation to the hospital is independently associated
with increased risk of short- and long-term all-cause
mortality, short- and long-term cardiovascular mortality,
and hospital admission for heart failure in patients with ST-
segment–elevation myocardial infarction.
• This indicates that the adrenomedullin system is activated
after ST-segment–elevation myocardial infarction and that
midregional proadrenomedullin measured in the early phase
after an ST-segment–elevation myocardial infarction may be
a useful marker of prognosis.
What Are the Clinical Implications?
• A single prognostic biomarker might be easier for physicians
to take into account for early risk stratiﬁcation instead of
several clinical markers.
• However, midregional proadrenomedullin only minimally
changed the discriminatory ability of a multivariable clinical
model for long-term all-cause mortality, whereas the
discriminatory ability for short-term mortality was not
signiﬁcantly changed.
• Future randomized clinical studies are needed to evaluate if
an early risk strategy with admission concentrations of
midregional proadrenomedullin, for example with a cut-off
concentration of 0.79 nmol/L, can improve clinical
outcomes.
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Ethics
The Regional Ethics Committee in Copenhagen approved the
study.19 The DANAMI-3 trial program was conducted in
compliance with the Helsinki II Declaration. Written informed
consent was obtained from all participants.
Blood Sampling
All blood samples were obtained immediately upon arrival in
the catheterization laboratory before PCI was initiated. In a
subset of patients additionally 2 samples were collected with
a median time of 5.7 hours (25th–75th percentiles, 5.2–6.6)
and of 12.8 hours (25th–75th percentiles, 11.6–15.7) after
presentation. Blood samples were collected into tubes
containing EDTA. After centrifugation, plasma was stored at
80°C until later biochemical analyses.
Biochemical Analysis
MR-proADM was measured using a chemiluminescence
immunoassay (BRAHMS MR-proADM KRYPTOR) on an auto-
mated platform (BRAHMS KRYPTOR compact PLUS, Thermo
Fisher Scientiﬁc, Hennigsdorf, Germany).23 The lower limit of
detection was 0.05 nmol/L. The functional assay sensitivity,
deﬁned as the MR-proADM concentration with an interassay
coefﬁcient of variation of <20%, was 0.25 nmol/L. Intra-assay
and interassay coefﬁcient of variation at different concentra-
tions of MR-proADM were as follows; between 0.2 and
0.5 nmol/L, ≤10% and ≤20%, respectively; and >6 nmol/L,
<3.5% and ≤6%, respectively.
We measured high-sensitivity cardiac troponin T (hs-cTnT)
using the Elecsys high Troponin T high-sensitive assay
(Cobas). The limit of detection was 5 ng/L and the 10% CV
precision was 13 ng/L. The 99th percentile concentration in
a healthy population is reported to be 14 ng/L.24 We
measured creatinine and hemoglobin by routine methods.
The estimated glomerular ﬁltration rate (eGFR) was calculated
using the Chronic Kidney Disease Epidemiology Collaboration
equation.25
Outcomes
The primary outcome was long-term all-cause mortality. All-
cause mortality and cardiovascular mortality within 30 days,
long-term cardiovascular mortality, and hospital admission
for heart failure were evaluated as secondary outcomes. All
study outcomes were identiﬁed using the National Danish
Heart Registry and were subsequently validated by an
independent clinical event committee using hospital records.
Deaths were classiﬁed as cardiovascular unless another
cause was obvious, as determined by the clinical event
committee. Hospital admission for heart failure was deﬁned
as development of heart failure after primary PCI, new
hospital admission to an acute care facility of at least
6 hours with a worsening of existing heart failure requiring
treatment, or extended index hospital admission because of
worsening heart failure.
Statistical Analysis
Patients were grouped according to quartiles of MR-proADM
concentrations. Baseline characteristics are presented as
numbers (percentages) for categorical variables and as
medians with 25th to 75th percentiles for continuous
variables. Baseline characteristics were compared between
groups by use of the Kruskal–Wallis rank-sum test for
continuous variables and the Cochran-Armitage, chi squared,
or Fisher’s exact test as appropriate for categorical variables.
Kaplan–Meier curves and log-rank tests were used to
compare unadjusted differences across baseline levels of MR-
proADM divided into quartiles. Hazard ratios (HR) were
assessed by use of univariate and multivariable Cox propor-
tional hazards models. Patients lost to follow-up because of
emigration were censored at date of emigration. Levels of MR-
proADM were transformed using a base 2-logarithmic trans-
formation, and therefore, the presented HRs refer to a
doubling in level of MR-proADM. Secondly, the two highest
quartiles of MR-proADM were compared individually with
quartile 1 and 2 as a combined reference.
For each outcome event, two multivariable models were
applied. Multivariable model 1 included adjustment for age
and sex, whereas multivariable model 2 was adjusted for age,
sex, time since onset of symptoms, left ventricular ejection
fraction, heart rate, eGFR, angiographic thrombolysis in
myocardial infarction (TIMI) ﬂow before primary PCI, anterior
myocardial infarction, log2-transformed peak concentrations
of hs-cTnT, and medical history of following variables:
diabetes mellitus, hypertension, history of smoking, previous
myocardial infarction, previous stroke, and congestive heart
failure.
Assumptions underlying the proportional hazard models
(proportional hazards and linearity of continuous variables)
were tested and found valid. We tested for interactions with
MR-proADM and age, sex, time since onset of symptoms,
diabetes mellitus, heart rate, left ventricular ejection fraction,
and hs-cTnT on all outcomes and were reported if signiﬁcant
after adjustment for multiple testing. To assess whether MR-
proADM was inﬂuenced by treatment allocation, we tested for
interactions with MR-proADM and randomization in iPOST,
DEFER, and PRIMULTI on all outcomes.
To assess the predictive effects of MR-proADM on 30-days
and 3-year all-cause mortality, we calculated the area under
the curve (AUC) of receiver operating characteristics and
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evaluated the effects of MR-proADM in addition to peak
concentrations of hs-cTnT and to models with well-established
risk factors and clinical variables (same variables as in the
multivariable Cox model 2) using the approach of DeLong
et al.26 By use of the Youden index, cut-off values for MR-
proADM were calculated for short- and long-term mortality,
respectively. Comparison between serial samples of MR-
proADM was performed with repeated measures analysis of
variance.
All tests were 2-sided, and a P value of <0.05 was
considered to indicate statistical signiﬁcance. All analyses
were performed with SAS statistical software, version 9.4
(SAS Institute, Chapel Hill, North Carolina, USA).
Results
Baseline Characteristics
Between March 21, 2011, and February 2, 2014, a total
number of 2239 patients were enrolled in the DANAMI-3 trial
at 4 different primary PCI centers. Blood samples for MR-
proADM measurements were collected between November
10, 2011, and February 2, 2014, at Rigshospitalet. In this
period, a total of 1292 consecutive patients were enrolled in
the DANAMI-3 trial at Rigshospitalet and MR-proADM was
measured in 1122 patients (86.8%) at admission (Figure 1).
The median interval from onset of symptoms until blood
sampling was 2.8 hours (25th–75th percentiles, 2.1–4.4).
MR-proADM concentrations at admission did not differ
considerably according to duration of symptoms (Figure S1).
There were some differences in baseline characteristics
between patients in this substudy and the remaining patients
in DANAMI-3: systolic and diastolic blood pressure, eGFR,
TIMI-ﬂow before PCI, the prevalence of hyperlipidemia, and
the prevalence of multivessel disease were signiﬁcantly higher
among patients with measured MR-proADM, whereas left
ventricular ejection fraction was signiﬁcantly lower among
these patients (Table S1).
Baseline characteristics of patients in this substudy,
according to quartiles of MR-proADM concentrations at
admission, are shown in Table 1. Median age was 62 years
(25th–75th percentiles, 53–70) and plasma concentrations of
MR-proADM ranged from 0.14 to 4.76 nmol/L with a median
of 0.64 nmol/L. All quartiles contained more men than
women, but the proportion of women increased with higher
quartile level. The proportion of patients with diabetes
mellitus, heart failure, and hypertension increased with higher
quartile level, as did age, body-mass index, and baseline and
peak hs-cTnT. In contrast, higher quartile level was associated
with lower levels of left ventricular ejection fraction,
hemoglobin, diastolic blood pressure, and eGFR.
Survival Analysis
Median follow-up was 1105 days (25th–75th percentiles,
917–1281) among survivors. Five patients emigrated 65 to
510 days after inclusion. Within 30 days 23 (2.1%) patients
died, all from cardiovascular causes. During follow-up, 80
(7.1%) deaths occurred of which 45 (4.0%) were from
cardiovascular causes and 38 (3.4%) patients were admitted
with heart failure. Of the 35 noncardiovascular deaths, 24
patients died from cancer, and 11 patients died from other
causes. Kaplan–Meier survival analysis showed that the
overall differences between quartiles of MR-proADM concen-
trations were signiﬁcant (P<0.0001, Figure 2). However, no
signiﬁcant difference was found between quartile 1 and 2
(P=0.27). The number of deaths from all causes increased
with higher quartile level; 4 (1.4%) in the ﬁrst quartile, 8 (2.8%)
in the second quartile, 17 (6.1%) in the third quartile and 51
(18.2%) in the fourth quartile, as did the number of
cardiovascular deaths; 4 (1.4%) in the ﬁrst quartile, 4 (1.4%)
in the second quartile, 8 (2.9%) in the third quartile and 29
(10.4%) in the fourth quartile.
In univariate analysis, 30-day mortality increased with
higher plasma concentrations of MR-proADM (HR, 3.93 per
doubling; 95% conﬁdence interval [CI], 2.51–6.14; P<0.0001)
(Table 2). This association remained signiﬁcant after adjusting
for age and sex (HR, 3.14; 95% CI, 1.86–5.33; P<0.0001), and
Figure 1. CONSORT study ﬂow diagram. MR-proADM indicates
midregional proadrenomedullin; TIMI-ﬂow, angiographic throm-
bolysis in myocardial infarction ﬂow.
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after additional adjustment in the multivariable model 2 (HR,
2.67; 95% CI, 1.01–7.11; P=0.049). These results were
identical for 30-day cardiovascular mortality, since all deaths
within 30 days were from cardiovascular cause.
For long-term all-cause mortality, univariate analysis
showed that a doubling of MR-proADM concentrations was
associated with a 3.43 increase in HR (95% CI, 2.67–4.41;
P<0.0001). After adjusting for age and sex, MR-proADM was
Table 1. Baseline Characteristics of the 1122 Patients With STEMI According to Quartiles of MR-proADM at Admission
All (N=1122)
MR-pro-ADM Quartiles (nmol/L)
P Value1st ≤0.52 (n=279)
2nd 0.53 to 0.64
(n=282)
3rd 0.65 to 0.78
(n=281)
4th ≥0.0.79
(n=280)
Male sex, n (%) 848 (75.6) 233 (83.5) 219 (77.7) 209 (74.4) 187 (66.8) <0.0001
Age, y 62 (53–70) 54 (47–62) 58 (52–66) 65 (55–71) 71 (62–80) <0.0001
Medical history
Previous myocardial infarction, n (%) 73 (6.5) 14 (5.0) 15 (15.3) 22 (7.8) 22 (7.9) 0.09
Congestive heart failure, n (%) 47 (4.2) 7 (2.5) 5 (1.8) 13 (4.6) 22 (7.9) 0.0004
Previous stroke, n (%) 49 (4.4) 9 (3.2) 9 (3.2) 15 (5.3) 16 (5.7) 0.08
Diabetes mellitus, n (%) 110 (9.8) 22 (7.9) 24 (8.5) 25 (8.9) 39 (13.9) 0.02
Hypertension, n (%) 450 (40.1) 82 (29.4) 100 (35.6) 115 (40.9) 153 (54.6) <0.0001
Hyperlipidemia, n (%) 393 (35.0) 94 (33.7) 107 (37.9) 93 (33.1) 99 (35.4) 1.0
History of smoking, n (%) 897 (80.0) 215 (77.1) 226 (80.1) 230 (81.9) 226 (80.7) 0.24
Body-mass index, kg/m2 26.6 (24.2–29.6) 26.5 (24.2–28.7) 26.0 (23.8–29.2) 26.6 (24.5–30.4) 27.1 (24.4–30.2) 0.03
Multivessel disease, n (%) 428 (38.2) 105 (37.6) 111 (39.4) 97 (34.5) 115 (41.1) 0.67
TIMI-flow before PCI, n (%) 0.50
0 572 (51.0) 145 (52.0) 131 (46.5) 147 (52.3) 149 (53.2)
1 95 (8.5) 24 (8.6) 31 (11.0) 20 (7.1) 20 (7.1)
2 199 (17.7) 49 (17.6) 45 (16.0) 55 (19.6) 50 (17.9)
3 256 (22.8) 61 (21.9) 75 (26.6) 59 (21.0) 61 (21.8)
Left ventricular ejection fraction, % 50 (40–55) 50 (45–55) 50 (40–55) 50 (40–55) 45 (35–50) <0.0001
Clinical data at admission
Heart rate, bpm 73 (61–87) 70 (60–84) 72.5 (61–87) 74 (64–84) 75 (59–92) 0.06
Systolic BP, mm Hg 133 (118–149) 133 (122–149) 131 (116–149) 134 (119–148) 131 (115–151) 0.29
Diastolic BP, mm Hg 82 (72–93) 84 (76–94) 82 (72–97) 84 (72–93.5) 80 (70–91) 0.003
Infarct location 0.07
Anterior, n (%) 478 (42.6) 105 (37.6) 139 (49.3) 123 (43.8) 111 (39.6)
Inferior, n (%) 595 (26.7) 162 (58.1) 130 (46.1) 142 (50.5) 161 (57.5)
Posterior, n (%) 47 (4.2) 12 (4.3) 12 (4.3) 16 (5.7) 7 (2.5)
Left bundle branch block, n (%) 2 (<1.0) 0 (0) 1 (<1.0) 0 (0) 1 (<1.0)
Laboratory values
Baseline hs-cTnT, ng/L 71 (27–190) 55 (23–146) 68 (25–186) 72 (29–155) 100 (34–353) <0.0001
Peak hs-cTnT, ng/L 2945
(1160–6270)
2625
(1130–5120)
2730
(1030–6070)
3340
(1155–6970)
3485
(1330–7490)
0.02
eGFR, mL/min per 1.73 m2 91 (76–100) 100 (93–108) 95 (85–103) 89 (77–97) 69 (53–86) <0.0001
Hemoglobin, mmol/L 8.7 (8.1–9.2) 8.8 (8.3–9.3) 8.8 (8.2–9.2) 8.7 (8.2–9.2) 8.5 (7.7–9.0) <0.0001
Data are presented as median values (25th–75th percentiles) for continuous variables and as numbers (percentages) for categorical variables. Unless indicated otherwise, the laboratory
values are from blood samples obtained at admission. BP indicates blood pressure; bpm, beats per minute; eGFR, estimated glomerular ﬁltration rate; hs-cTnT, high-sensitivity cardiac
troponin T; MR-proADM, midregional proadrenomedullin; PCI, percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial infarction; TIMI-ﬂow, angiographic thrombolysis
in myocardial infarction ﬂow.
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still associated with long-term all-cause mortality (HR, 2.59;
95% CI, 1.91–3.52; P<0.0001) and remained signiﬁcant after
additional multivariable adjustment (HR, 3.23; 95% CI, 1.97–
5.29; P<0.0001). Besides elevated MR-proADM concentra-
tions, older age (HR, 2.44 per 10 year increase; 95% CI, 1.82–
3.25), lower left ventricular ejection fraction (HR, 0.97 per 1%
increase; 95% CI, 0.94–1.00), diabetes mellitus (HR, 2.28;
95% CI, 1.20–4.34), history of smoking (HR, 2.43; 95% CI,
1.21–4.90) and higher heart rate (HR, 1.18 per 10 beats per
minute; 95% CI, 1.05–1.33) were signiﬁcantly associated with
higher risk of death in multivariable analysis.
In univariate Cox analysis with MR-proADM as a categorical
variable the HRs in quartile 3 and 4 were; 2.87 (95% CI, 1.37–
6.01; P=0.005) and 9.16 (95% CI, 4.88–17.18; P<0.0001; see
Figure 3) with the two ﬁrst quartiles as a combined reference.
This association remained signiﬁcant in quartile 4 when
adjusted for age and sex (HR, 4.70; 95% CI, 2.37–9.33;
P<0.0001) and after additional multivariable adjustment (HR,
4.25; 95% CI, 1.98–9.15; P=0.0002).
Interaction analysis did not reveal any important interac-
tion with randomization in DANAMI-3-DEFER, DANAMI-3-
PRIMULTI or DANAMI-3-iPOST (data not shown).
Figure 2. Overall survival among patients with STEMI, according to quartiles of admission MR-proADM.
The MR-proADM levels were as follows: ﬁrst quartile ≤0.52 nmol/L, second quartile 0.53 to 0.64 nmol/L,
third quartile 0.65 to 0.78 nmol/L and fourth quartile ≥0.79 nmol/L. MR-proADM indicates midregional
proadrenomedullin; STEMI, ST-segment–elevation myocardial infarction.
Table 2. Associations Between Admission MR-proADM and Prognosis
Outcome
Univariate Model Multivariable Model 1 Multivariable Model 2
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
30-day all-cause mortality 3.93 (2.51–6.14) <0.0001 3.14 (1.86–5.33) <0.0001 2.67 (1.01–7.11) 0.049
30-day cardiovascular mortality 3.93 (2.51–6.14) <0.0001 3.14 (1.86–5.33) <0.0001 2.67 (1.01–7.11) 0.049
Long-term all-cause mortality 3.43 (2.67–4.41) <0.0001 2.59 (1.91–3.52) <0.0001 3.23 (1.97–5.29) <0.0001
Long-term cardiovascular mortality 3.64 (2.63–5.04) <0.0001 3.06 (2.10–4.45) <0.0001 3.17 (1.56–6.42) 0.002
Hospital admission for heart failure 3.45 (2.40–5.00) <0.0001 3.17 (2.12–4.73) <0.0001 2.71 (1.32–5.58) 0.007
Model 1 was adjusted for age and sex. Model 2 was adjusted additionally for age, sex, time since onset of symptoms, left ventricular ejection fraction, heart rate, estimated glomerular
ﬁltration rate, TIMI-ﬂow before primary PCI, anterior myocardial infarction, log2-transformed peak concentrations of hs-cTnT, and medical history of the following variables: diabetes
mellitus, hypertension, history of smoking, previous myocardial infarction, previous stroke, and congestive heart failure. CI indicates conﬁdence interval; HR, hazard ratio; hs-cTnT, high-
sensitivity cardiac troponin T; MR-proADM, midregional proadrenomedullin; PCI, primary percutaneous coronary intervention; TIMI-ﬂow, angiographic thrombolysis in myocardial infarction
ﬂow.
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For long-term cardiovascular mortality and hospital admis-
sion for heart failure, analysis of elevated MR-proADM
concentrations in multivariable model 2 revealed HRs of
3.17 (95% CI, 1.56–6.42; P=0.002) and 2.71 (95% CI, 1.32–
5.58; P=0.007), respectively (see Table 2).
Receiver Operating Characteristics Analysis
Receiver operating characteristics analysis of MR-proADM on
30-day mortality yielded an AUC of 0.77 (95% CI, 0.65–0.88;
Table 3). AUC of peak concentrations of hs-cTnT was 0.68
(95% CI 0.55–0.81) and improved signiﬁcantly to 0.83 (95%
CI, 0.73–0.92; P=0.03) after the addition of MR-proADM,
whereas hs-cTnT did not signiﬁcantly improve the discrimina-
tory ability of MR-proADM (P=0.07). For a multivariable model
including the same variables as in the multivariable Cox model
2, the AUC was 0.91 (95% CI, 0.85–0.97) and did not change
signiﬁcantly with the inclusion of MR-proADM (AUC 0.92, 95%
CI, 0.86–0.98; P=0.23). For long-term mortality, the AUC of
MR-proADM was 0.78 (95% CI, 0.73–0.84; Table 3), whereas
Figure 3. Univariate and multivariable cox analysis for all-cause mortality according to quartiles of MR-
proADM among patients with STEMI. Model 1 was adjusted for age and sex. Model 2 was adjusted
additionally for age, sex, time since onset of symptoms, left ventricular ejection fraction, heart rate,
estimated glomerular ﬁltration rate, TIMI-ﬂow before primary PCI, anterior myocardial infarction, log2-
transformed peak concentrations of hs-cTnT, and medical history of following variables: diabetes mellitus,
hypertension, history of smoking, previous myocardial infarction, previous stroke, and congestive heart
failure. CI indicates conﬁdence interval; HR, hazard ratio; hs-cTnT, high-sensitivity cardiac troponin T; MR-
proADM, midregional proadrenomedullin; PCI, primary percutaneous coronary intervention; STEMI, ST-
segment–elevation myocardial infarction; TIMI-ﬂow, angiographic thrombolysis in myocardial infarction ﬂow.
Table 3. Area Under the Curve of Receiver Operating Characteristics for 30-Day and 3-Year All-Cause Mortality
Outcome Model AUC 95% CI P Value for Test*
30-day mortality MR-proADM 0.77 0.65 to 0.88 
Peak hs-cTnT 0.68 0.55 to 0.81 
Peak hs-cTnT+MR-proADM 0.83 0.73 to 0.92 0.03
Multivariable model 0.91 0.85 to 0.97 
Multivariable model+MR-proADM 0.92 0.86 to 0.98 0.23
3-year mortality MR-proADM 0.78 0.73 to 0.84 
Peak hs-cTnT 0.59 0.51 to 0.66 
Peak hs-cTnT+MR-proADM 0.78 0.72 to 0.84 <0.0001
Multivariable model 0.84 0.78 to 0.90 
Multivariable model+MR-proADM 0.85 0.80 to 0.91 0.02
AUC indicates area under the curve; CI, conﬁdence interval; hs-cTnT, high-sensitivity cardiac troponin T; MR-proADM, midregional proadrenomedullin.
*Test for the effect of MR-proADM in addition to peak hs-cTnT and the multivariable models (same variables as in the multivariable Cox regression model 2).
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the AUC of the multivariable model was 0.84 (95% CI, 0.78–
0.90) and increased minimally but signiﬁcantly to 0.85 (95%
CI, 0.80–0.91; P=0.02) after the addition of MR-proADM.
Receiver operating characteristics analysis provided a cut-off
value of 0.87 nmol/L (65.2% sensitivity, 84.1% speciﬁcity) for
short-term mortality and a cut-off value of 0.80 nmol/L
(65.3% sensitivity, 78.4% speciﬁcity) for long-term mortality.
Serial Measurements of MR-proADM
Serial measurements with 3 samples of MR-proADM were
performed in 448 patients. Repeated measures analysis of
variance showed that MR-proADM concentrations increased
signiﬁcantly (P<0.0001) in this subgroup of patients with the
following median levels for sample 1, 2, and 3; 0.64 nmol/L
(25th–75th percentiles, 0.54–0.78), 0.73 nmol/L (0.62–0.92),
and 0.76 nmol/L (0.63–0.94).
Discussion
Our study shows that MR-proADM elevation at presentation to
the hospital in patients with STEMI prior to PCI is indepen-
dently associated with long-term all-cause mortality, long-
term cardiovascular mortality, and hospital admission for
heart failure, whereas the association with short-term all-
cause mortality and short-term cardiovascular mortality was
borderline signiﬁcant. Furthermore, MR-proADM concentra-
tions seem relatively unchanged when compared with dura-
tion of symptoms after an STEMI, which contrast other
biomarkers such as troponins and copeptin.27–29 This is the
ﬁrst study on MR-proADM measurement at admission in a
large STEMI cohort prior to PCI. Thus, these results add
evidence to available information about the value of MR-
proADM as a possible marker of risk in patients presenting
with acute chest pain,30,31 acute dyspnea,32 stable angina
pectoris,33 non-ST-segment–elevation myocardial infarction
(NSTEMI)34 and mixed populations of acute coronary
syndrome.33,35,36
Patients with plasma concentrations of 0.79 nmol/L or
higher (upper quartile) were of particularly high risk with early
separation of mortality. This threshold effect for MR-proADM is
supported by previous ﬁndings from studies on the prognostic
value of ADM and MR-proADM after acute myocardial infarc-
tion. Katayama et al reported that only a high level of plasma
ADM in STEMI patients was independently associated with 30-
day mortality when measured 24 hours after onset of chest
pain.15 The LAMP (Leicester Acute Myocardial Infarction
Peptide) study showed that MR-proADM was most informative
with concentrations above the fourth quartile (1.04 nmol/L).35
The LAMP study included 983 patients with acute myocardial
infarction, either STEMI or NSTEMI, with a median follow-up of
342 days and with MR-proADM concentrations measured at
discharge (3–5 days after the event). They concluded that
discharge concentrations of MR-proADM added predictive
information to N-terminal pro-B type natriuretic peptide (NT-
pro-BNP). Our study differs from the LAMP study, as we
examined admission concentrations of MR-proADM in blood
samples obtained immediately before primary PCI was per-
formed in patients with STEMI.
Our reported AUC of 0.78 on long-term mortality is
consistent with that reported in the LAMP study (0.77) for the
combined end point of death and heart failure.35 In a long-
term follow-up study (median 3.6 years) of a subgroup of
patients with acute coronary syndrome, Wild et al found an
AUC of 0.64 on a combined end point of cardiovascular death
and non-fatal myocardial infarction after 2 years and reported
a cut-off value of 0.70 nmol/L.33 Tzikas et al identiﬁed
patients at high risk in the upper tertile (0.71 nmol/L) of
patients with acute chest pain.31 These cut-off values are
relatively similar to our cut-off value for long-term mortality
(0.80 nmol/L) and for the upper quartile (≥0.79 nmol/L).
Plasma concentrations in healthy individuals have been
reported to be 0.4 nmol/L.37,38
In this study, admission concentrations of MR-proADM
showed superior prognostic value for both short- and long-
term mortality compared with peak concentrations of hs-cTnT
and the discriminatory ability of hs-cTnT improved with the
addition of MR-proADM. Investigators of the LAMP II study
showed that admission MR-proADM was a stronger predictor
than discharge concentrations, and that it was the only
independent predictor (superior to NT-proBNP and the Global
Registry of Acute Coronary Events [GRACE] risk score) of early
mortality in a large cohort of patients with NSTEMI.34
The LAMP II study reported a considerably higher AUC
(0.90) and a higher optimal cut-off value (1.11 nmol/L) for
short-term mortality compared with our study (0.87 nmol/L).
Possible reasons for this discrepancy are that we included
younger patients, fewer women, and patients with better renal
function, and that we excluded patients at high risk because
of unconsciousness or cardiogenic shock, stent thrombosis,
or need of urgent surgery. This, along with the fact that only a
limited number of deaths occurred, may explain why we only
found a borderline signiﬁcant association between elevated
concentrations of MR-proADM and short-term all-cause
mortality after multivariable adjustment.
In the LAMP II study, preliminary data suggested that MR-
proADM concentrations above the median (>0.81 nmol/L)
could help to identify patients who would beneﬁt from
revascularization. We were not able to replicate such data as
all patients had STEMI. However, this would be relevant to
investigate in future studies.
As might be expected, cardiovascular death was the
predominant cause of death within the ﬁrst month (23 of 23
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deaths).5 In full follow-up, non-cardiovascular causes of death
were almost as frequent as cardiovascular causes of death
(35 of 80 deaths). This suggests that the risk of cardiovas-
cular events decreases over time, and therefore, risk assess-
ment is particularly indicated in the early phase after an
STEMI. However, non-cardiovascular death is likely to be
inﬂuenced by cardiovascular disease. ADM is secreted in
response to multiple conditions including shear stress,
increased cardiac work load, ischemia, hypoxia, acidosis,
catecholamines, angiotensin II, vasopressin, and inﬂammatory
damage by cytokines.9 Through vasodilator, diuretic, natri-
uretic, and inotropic properties, ADM may try to regulate
blood pressure and cardiac contractility, and maintain water
and electrolyte homeostasis.6,9 Thus, increments of ADM in
STEMI patients most likely reﬂect a counterbalanced
response to ischemic burden and hemodynamic stress.
Moreover, the level of ADM is increased in relation to the
severity of heart failure.39
Plasma ADM concentrations seem to peak between 24 to
48 hours after onset of symptoms;10,11 nevertheless, we
showed that elevation of MR-proADM in STEMI patients prior
to PCI were independently associated with poor outcome. In
our study, MR-proADM at admission appeared stable accord-
ing to duration of symptoms and was relatively stable in later
serial measurements, though we observed a doubtful clinically
relevant but signiﬁcant increase of MR-proADM; this contrasts
levels of troponins which have delayed elevations of circulat-
ing levels27,28 and levels of copeptin which seem to peak in
the early phase after an acute myocardial infarction with a
subsequently rapid decline.29
Study Limitations
This study was a single center, post hoc substudy. We
observed minor differences in systolic and diastolic blood
pressure, eGFR, TIMI-ﬂow before PCI and multivessel disease
between patients in our substudy and the remaining DANAMI-
3 trial participants. The frozen samples were stored for up to
5 years before analysis of MR-proADM, potentially leading to
biomarker degradation, although this marker has previously
been shown to be stable under these conditions.23
Conclusions
Elevated plasma concentrations of MR-proADM at admission
were associated with an increased risk of short- and long-term
all-cause mortality, short- and long-term cardiovascular mor-
tality, and hospital admission for heart failure, in patients with
STEMI, independent of established risk factors. In addition,
patients with MR-proADM concentrations of 0.79 nmol/L or
higher were of particularly high risk, and MR-proADM
improved the discriminatory ability of peak hs-cTnT for both
short-term and long-term all-cause mortality. These ﬁndings
indicate that MR-proADM, measured at admission, may be a
marker of prognosis after STEMI. However, the association
between elevated MR-proADM and short-term mortality only
reached borderline signiﬁcance after multivariable adjust-
ment, and MR-proADM did not add clinical relevant prognostic
information to multivariable receiver operating characteristics
analysis on either short- or long-term all-cause mortality.
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Table S1. Baseline characteristics of included and excluded patients. 
 
Variables MR-pro-ADM missing 
(n = 1117) 
MR-pro-ADM measured 
(n = 1122) 
p Value 
Male sex, (%) 872 (78.1) 848 (75.6) 0.17 
Age, years  63 (54-71) 62 (53-70) 0.05 
Previous myocardial infarction, (%) 59 (5.3) 73 (6.5) 0.22 
Cardiovascular risk factors    
Diabetes mellitus, (%) 95 (8.5) 110 (9.8) 0.29 
Hypertension, (%) 416 (37.7) 450 (40.1) 0.23 
Hyperlipidemia, (%) 296 (27.0) 393 (35.0) <0.0001 
History of smoking, (%) 864 (78.5) 897 (80.0) 0.39 
Body mass index, kg/m2 26.3 (24.1-29.2) 26.6 (24.2-29.6) 0.14 
Multivessel disease, (%) 347 (31.1) 428 (38.2) 0.0004 
TIMI-flow before PCI (%)   <0.0001 
0 725 (65.0) 572 (51.0)  
1 90 (8.1) 95 (8.5)  
2 105 (9.4) 199 (17.7)  
3 196 (17.6) 256 (22.8)  
Left ventricular ejection fraction, % 50 (40-55) 50 (40-55) <0.0001 
Clinical data at admission    
Heart rate, bpm 73 (60-85) 73 (61-87) 0.19 
Systolic BP, mm Hg 130 (115-145) 133 (118-149) 0.01 
Diastolic BP, mm Hg 80 (68-90) 82 (72-93) <0.0001 
Infarct location   0.05 
Anterior, (%) 473 (42.4) 478 (42.6)  
Inferior, (%) 566 (50.7) 595 (53.0)  
Posterior, (%) 73 (6.5) 47 (4.2)  
Left bundle branch block, (%)  5 (<1.0) 2 (<1.0)  
Laboratory Values    
Peak hs-cTnT, ng/L 3250 (1150-6465) 2945 (1160-6270) 0.54 
eGFR, ml/min/1.73 m2 90 (74-100) 91 (76-101) 0.03 
Hemoglobin, mmol/L 8.6 (8.1-9.2) 8.7 (8.1-9.2) 0.07 
 
 
Data are presented as median values (25th to 75th percentiles) for continuous variables and as numbers (percentages) 
for categorical variables. Unless indicated otherwise, the laboratory values are from blood samples obtained at 
admission. BP indicates blood pressure; bpm, beats per minute; eGFR, estimated glomerular filtration rate; hs-cTnT, 
high-sensitive cardiac troponin T; MR-proADM, midregional proadrenomedullin; PCI, percutaneous coronary 
intervention; STEMI, ST-segment elevation myocardial infarction; TIMI-flow, angiographic thrombolysis in 
myocardial infarction flow. 
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Figure S1. Levels of MR-proADM According to Duration of Symptoms Until Baseline Blood Sampling. 
 
 
MR-proADM indicates midregional proadrenomedullin.  
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